INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...
SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] ...
INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results